(PARIS, FRANCE) - Experts participating in a European Clinical Consensus Conference (CCC) have concluded that research into the use of renal denervation for high blood pressure in patients unable to control the disease using a multi-drug regimen should not be abandoned until high-quality research is completed according to agreed-upon standards. [1]

"Focused, collaborative high-quality research will be necessary to ensure that future patients are neither denied an effective therapy, nor needlessly put at risk from procedures that bring no benefits," the authors, led by Dr. Felix Mahfoud of Saarland University Hospital, Homburg/Saar, Germany, write.

The group's conclusions, including a roadmap for future research into non-drug treatment for resistant hypertension, is published today in the European Heart Journal and are the focus of a special session Wednesday at EuroPCR 2015.

Observational studies as well as three randomised, controlled trials support the safety and efficacy of the therapy, but smaller studies as well as the large, single-blind, randomised, sham-controlled Symplicity HTN-3 trial failed to show any benefit to renal denervation. The therapy uses radiofrequency energy or other ablation methods, delivered by a catheter, to disrupt the nerve signals travelling to and from the kidney, with the aim of lowering systolic blood pressure. In the wake of the Symplicity HTN-3, some clinicians have refused to endorse the procedure. Others, pointing to a significant unmet need, have argued it's too soon to abandon the investigative procedure, the CCC paper notes.

In their consensus document, Mahfoud and colleagues examine procedural aspects, patient selection, and clinical trials, reaching a number of important conclusions.

• At the procedural level, practitioners have learned that getting effective results with renal denervation is not as simple as it first seemed, particularly as it applies to achieving "complete" ablation. Better preclinical studies are needed, as are reliable markers to determine whether or not nerve ablation has been successful.
• In terms of the appropriate patient group, the CCC concluded that selecting "last resort" patients with high systolic blood pressure taking three or more drugs may not necessarily be the best patients in whom to use or indeed study the emerging therapy. Younger patients with moderate hypertension might actually have anatomy more suited to lasting results.
• With regards to appropriate clinical trials, the CCC strongly supports the use of ambulatory blood pressure monitoring, both to determine the response to renal denervation, but also as a prerequisite for enrolling a patient in a RDN study. Other key factors for future research include how to measure adherence to blood pressure drugs, and how to standardize treatment during the study "run-in period." Finally, the requirement of using a sham-control procedure--and its inherent risks--may need to be dispensed with if lower-risk hypertension patients are studied, they propose.

Most of all, renal denervation research is in desperate need of standardization, the authors write. "Treatments, populations, methods, and adherence measures need to be highly consistent to avoid inconclusive or biased results."

"The open questions around renal denervation touch upon a large number of specialties from interventional cardiologists to hypertension experts and molecular biologists," Dr. Mahfoud commented. "The future of the therapy will depend on closer interactions at all levels, necessitating focused collaborative high-quality research, smaller projects targeting specific questions as well as large-scale multidisciplinary research programmes."

###

The CCC was supported by an unrestricted educational grant from Europa Organisation, Toulouse, France. Dr. Mahfoud disclosed research grants to his institution from Medtronic/Ardian, St. Jude Medical, and Recor and speaker honorarium from Medtronic/Ardian and St. Jude Medical.

Contact: Felix Mahfoud This e-mail address is being protected from spambots. You need JavaScript enabled to view it >

The Clinical Consensus Group Report will be published May 19 at 8:00 Central European Summer Time. A special session at EuroPCR 2015 focused on the CCC Renal Denervation Findings entitled "Interventional Hypertension Treatment: Moving Forward" will take place Wednesday May 20 from 14:40-16:40 in Room 242AB.

1. Mahfoud F, Bohm M, Azizi M, et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J 2015; DOI: doi:10.1093/eurheartj/ehv192

Notes to Editors

For more information on the abstracts featured in this press release, please contact Isabelle Uzielli, email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it Further information on press registration may be found at http://www.europcr.com/page/press/619-press.html

What is EuroPCR?

EuroPCR, the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI), a registered branch of the European Society of Cardiology, is the world-leading course in interventional medicine. PCR has established a distinctive format for educational activities in the field of cardiovascular interventions. Beyond its flagship course in Paris that gathers more than 12,000 participants every year, PCR organises annual courses in Singapore; London, UK; Dubai, EAU; Johannesburg, RSA; Istanbul, Turkey; Chengdu, China; and Tokyo, Japan.

For further information on EuroPCR, AsiaPCR/SingLIVE, PCR London Valves, GulfPCR-GIM, AfricaPCR, PCR Istanbul Peripheral, PCR-CIT China Chengdu Valves, PCR Tokyo Valves & PCR, please contact: Anne-Sophie Lartigau at This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

For more information, please visit http://www.europcr.com

...